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Plant specialized metabolites (i.e. secondary metabolites) have been employed by humans for centuries in 
traditional and modern medicine. They remain an important source for the discovery of new pharmaceuticals 
and nutraceuticals. Montbretin A (MbA) is a complex acylated flavonoid glycoside discovered in the below-
ground storage organs (corms) of the ornamental plant montbretia (Crocosmia x crocosmiiflora). MbA a highly 
potent and selective inhibitor of the human pancreatic α-amylase (HPA), a key enzyme in starch degradation. 
MbA is being tested for the treatment of type-2 diabetes. However, due to low abundance of MbA in montbretia 
plants and due the complex chemical structure of MbA, natural product extraction and chemical synthesis are 
insufficient for MbA production. Our goal is to develop a heterologous plant production system or a microbial 
production system for MbA. This requires knowledge of the genes, enzymes and regulating factors of the MbA 
biosynthetic system in montbretia. We achieved the discovery of the complete biosynthetic pathway of MbA 
using an approach that combined knowledge of montbretia biology, metabolite profiling, differential 
transcriptome analysis, cDNA cloning, heterologous gene expression in E. coli, yeast and tobacco, and enzyme 
biochemistry. This includes the discovery of five new UDP-sugar dependent glycosyltransferases (UGTs) and a 
BAHD-acyltransferases (AT) which together catalyze the complete assembly of MbA from its different building 
blocks. To reconstruct MbA production in tobacco (Nicotiana benthamiana) we enhanced the biosynthesis of 
flavonol precursors using genes for myricetin biosynthesis and transcription factors from montbtretia, which 
were stacked with genes of the MbA assembly pathway.  We will highlight both challenges and opportunities of 
exploring novel biosynthetic systems of plant specialized metabolites for the development of new drugs, and 
bioproducts in general. 
 
 
